The present disclosure provides a biocompatible polymer, and the polymer includes the embolic microbead including an iron adsorption block capable of adsorbing an iron component. The embolic microbead according to the an exemplary embodiment of the present disclosure adsorbs iron and thus effectively blocks an iron component delivered to cancer cells, and when used in embolization, it has an improved effect in treating cancers, such as liver cancer.

Provided are orthopedic implants and systems and kits containing orthopedic implants that include biodegradable polymer thin films containing an antimicrobial agent, wherein the implants produce an effective zone of inhibition around a periphery of the surface of the implant and do not produce a loss of release torque between interlocking implant components.

This invention relates to novel scar management products and methods of reducing dermal scars resulting from various types of dermal injuries while simultaneously reducing pruritis. Particularly, this invention relates to scar management products, each of which incorporate an antipruritic agent, that reduce and/or prevent dermal scarring and pruritis.

The present invention relates to a raw material for a bio-3D printing support and, more specifically, to a novel type bio-3D printing support material for tissue engineering, a method for manufacturing a three-dimensional support by using the same, and a 3D-printing three-dimensional support manufactured thereby, the raw material: being non-toxic and implementing excellent biocompatibility and cell adhesion since a raw material for a tissue engineering support (scaffold) produced by bio-3D printing technology, a specific fatty acid and a fatty alcohol (phase change material) derived from a natural source having a low melting point and a low molecular weight are used; and, in particular, allowing a phase change to easily occur at a temperature similar to body temperature such that a process is simplified and cells or growth factors can be mixed.

It is provided a composition comprising phytic acid or a pharmaceutically acceptable salt thereof, for use in reducing or preventing microorganisms' proliferation and/or encrustations caused by a urinary tract device implanted in a subject, thereby preventing or treating clinical complications related to microorganisms' proliferation and/or encrustations. The composition can further comprise a urine acidifier such as methionine, a crystallization inhibitor such as theobromine and/or other agents.

The present disclosure is directed toward drug coated balloons, and in particular to drug coated balloons having a drug coating layer that primarily uses therapeutic agents alone for improving the quality of treatments in which drug coated balloons are utilized. Particular aspects may be directed to drug coated balloon having an outer surface, and a drug coating layer on the outer surface of the balloon. The drug coating layer includes at least one therapeutic agent and is substantially free of excipients.

A surgical type face mask having a substrate forming an outer layer. The outer layer being treated with a water-based polymer containing at least one photosensitizer in sufficient quantity to impart a characteristic color. In the presence of visible light, the water based polymer generates therapeutically useful quantities of singlet oxygen for treatment, by inhalation thereof, of respiratory infections and cancers.

A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second polymer includes an alginate. The second coating has a hemostatic agent dispersed in the second polymer such that the second polymer releases the hemostatic agent as the second polymer degrades. The hemostatic agent is selected from epinephrine, tranexamic acid, chitosan and oxidized regenerated cellulose. In some embodiments, systems and methods are disclosed.

A surgical device includes a substrate and a first coating that covers at least a portion of the substrate. The first coating includes a first polymer. The first coating having antibiotics dispersed in the first polymer such that the first polymer releases the antibiotics as the first polymer degrades. A second coating covers at least a portion of the first coating. The second coating includes a second polymer. The second coating has ellagic acid dispersed in the second polymer such that the second polymer releases the ellagic acid as the second polymer degrades. In some embodiments, systems and methods are disclosed.

The present invention relates to a polyurethane composition with antimicrobial properties, a polyurethane foam or coating comprising said polyurethane composition, an article prepared from said composition, foam or coating, a process for the preparation of said composition, the use of a complexing agent and an antimicrobial agent for the preparation of said composition or for imparting antimicrobial properties to a polyurethane composition, and a kit of components for preparing said composition. A cooperative effect is observed when specific complexing agents are combined with specific organic antimicrobially active components within the polyurethane composition.